In India, slightly more than one million new cases of cancer are diagnosed every year in a population of 1.2 billion, and the number of new cancer cases is projected to nearly double within the next 20 years. In 2012 alone, an estimated 600,000 to 700,000 deaths in India were caused by cancer.
Delivering affordable and effective cancer care is one of India's greatest public health challenges. Mylan is helping to address this growing public health concern through its Onco Care division, launched in January 2014. Mylan’s oncology portfolio in India includes high quality, affordable cancer-related cytotoxic and targeted therapies for common types of cancer, such as breast, lung and colorectal.
In February 2014, Mylan launched the world’s first Trastuzumab biosimilar under the brand name HertrazTM for the treatment of HER2-positive metastatic breast cancer. To further its commitment to providing holistic breast cancer care, Mylan launched Ashray™, a unique initiative that addresses the gaps in HER2-positive metastatic breast cancer management by offering patients financial, emotional and psychological support.